ADHD in Females: Substance Use Risk & Treatment Gaps

ADHD in Females: Investigating Substance Use Risk and Treatment Gaps

For decades, Attention-Deficit/Hyperactivity Disorder (ADHD) was conceptualized as a condition that primarily affected boys -- characterized by hyperactive, impulsive, disruptive behavior that was impossible for teachers and parents to miss. This framing shaped diagnostic criteria, informed clinical training, and directed research funding toward male-dominated samples. The consequence has been a systematic underrecognition of ADHD in females that persists despite growing awareness: girls and women with ADHD are diagnosed later, treated less aggressively, and remain significantly underrepresented in the research literature.

The Sultan Lab for Mental Health Informatics at Columbia University Irving Medical Center is addressing this gap through a large-scale analysis of ADHD diagnosis and substance use patterns in females using the IBM MarketScan Commercial Claims and Encounters database. Led by Dr. Ryan Sultan, this study represents one of the first comprehensive examinations of how ADHD treatment patterns in females relate to subsequent substance use outcomes using real-world insurance claims data covering millions of commercially insured Americans.

The Gender Gap in ADHD: Scope of the Problem

Underdiagnosis and Late Diagnosis

Epidemiologic studies estimate that ADHD affects males and females at a ratio of approximately 2:1 in population-based samples, yet clinical samples show ratios as high as 9:1 -- meaning the vast majority of females with ADHD never receive a clinical diagnosis. This discrepancy reflects systematic biases in recognition rather than genuine differences in prevalence.

Multiple factors contribute to underdiagnosis of ADHD in females:

Symptom presentation: Females with ADHD more frequently present with predominantly inattentive symptoms rather than the hyperactive-impulsive symptoms that prompt clinical referral. Inattention manifests as daydreaming, disorganization, and difficulty sustaining effort -- symptoms that are less disruptive to others and therefore less likely to trigger evaluation.
Compensatory strategies: Girls with ADHD often develop compensatory strategies at an earlier age, including working harder to maintain grades, relying on social skills to mask disorganization, and internalizing their struggles rather than acting out. These strategies can sustain adequate performance through childhood but often collapse under increasing demands in adolescence or adulthood.
Diagnostic overshadowing: Symptoms of ADHD in females frequently overlap with or are attributed to anxiety, depression, or emotional dysregulation. Clinicians may diagnose and treat the comorbid condition without recognizing the underlying ADHD that is driving or exacerbating it.
Referral bias: Teachers and parents are less likely to refer girls for ADHD evaluation because their behavior does not disrupt the classroom. The referring complaint that typically initiates ADHD evaluation -- a child who cannot sit still, talks out of turn, or is physically aggressive -- describes the prototypical male presentation.

Consequences of Delayed Recognition

The downstream consequences of late ADHD diagnosis in females are substantial. By the time many women receive an ADHD diagnosis in their 20s, 30s, or 40s, they have accumulated years of academic underperformance relative to their cognitive ability, relationship difficulties, occupational instability, and internalized feelings of inadequacy. The chronic experience of struggling without explanation often gives rise to secondary anxiety and depression, which then become the primary focus of treatment while the underlying ADHD remains unaddressed.

Critically, the period between symptom onset and diagnosis represents a window of vulnerability during which females with unrecognized ADHD may turn to substances as a means of self-medication or coping. This is the central hypothesis that the Sultan Lab's MarketScan study is designed to test.

Study Design: MarketScan Analysis

Data Source

MarketScan Commercial Claims Database

Coverage: 200+ million commercially insured individuals across the United States
Data type: Longitudinal medical and pharmacy claims data
Key variables: Diagnosis codes (ICD-9/ICD-10), prescription fills, procedure codes, provider encounters, demographic information
Strengths: Ability to follow individuals over time, track diagnostic sequences, identify medication adherence patterns, and examine healthcare utilization outcomes

The MarketScan database provides the longitudinal architecture necessary to address questions about temporal relationships between ADHD diagnosis, treatment initiation, and substance use outcomes. Unlike cross-sectional surveys, claims data allows the research team to observe the sequence of events in individual patients' care trajectories -- when ADHD was first diagnosed, what treatment was initiated, how consistently it was maintained, and whether substance use-related diagnoses subsequently appeared.

Research Questions

The study addresses several interconnected questions about ADHD in females:

Research Domain	Key Questions
Diagnostic Patterns	At what ages are females diagnosed with ADHD compared to males? How do comorbidity profiles differ at the time of diagnosis? What proportion of females receive an anxiety or depression diagnosis before ADHD is identified?
Treatment Initiation	Following ADHD diagnosis, how quickly do females receive stimulant medication compared to males? What proportion receive non-stimulant medications or no pharmacotherapy? Are there differences in prescriber type (psychiatry vs. primary care)?
Substance Use Outcomes	Do females with ADHD have elevated rates of substance use-related diagnoses compared to females without ADHD? Does the timing of ADHD diagnosis (earlier vs. later) affect substance use risk? Is consistent stimulant treatment associated with reduced substance use-related healthcare utilization?
Treatment Gaps	Among females diagnosed with ADHD, what proportion have gaps in stimulant treatment? Do treatment gaps correlate with increased substance use risk? Are there age-specific patterns in treatment discontinuation?

Methodology

The study employs a retrospective cohort design identifying females with new ADHD diagnoses in the MarketScan database and following them longitudinally to examine treatment patterns and substance use outcomes. Statistical methods include propensity score matching to control for confounders, survival analysis to model time-to-event outcomes, and stratified analyses by age group to examine whether the relationship between ADHD treatment and substance use varies across the lifespan.

A comparison cohort of females without ADHD, matched on age, enrollment period, and region, provides a baseline against which substance use rates can be measured. Additionally, within the ADHD cohort, the study compares outcomes between females who receive consistent stimulant treatment and those with interrupted or absent pharmacotherapy.

Connection to the IRB 2026 NLP Study

The MarketScan analysis is complemented by a parallel study using Natural Language Processing (NLP) to analyze electronic health record data from Columbia-affiliated NewYork-Presbyterian facilities. This IRB-approved study, led by Drs. Frances Levin and Xuhai "Orson" Xu with Dr. Sultan's involvement through NYSPI, applies NLP models to extract substance use documentation from unstructured clinical notes -- the narrative text that clinicians write during patient encounters.

While MarketScan provides breadth through its massive sample size and national coverage, the NLP-based EHR study provides depth by capturing clinical details that do not appear in claims data: the nuanced descriptions of substance use patterns, family history, psychosocial stressors, and treatment responses documented in progress notes, psychiatric evaluations, and discharge summaries. Together, these complementary approaches create a more complete picture of how ADHD and substance use interact in females.

Why This Research Matters

Clinical Implications for Women with ADHD

If the study confirms that delayed ADHD diagnosis and inconsistent treatment are associated with elevated substance use risk in females, the clinical implications are substantial. Screening protocols in primary care and mental health settings may need to be revised to identify ADHD in females at earlier ages, particularly among girls presenting with anxiety, depression, or academic underperformance that appears disproportionate to their cognitive ability.

For clinicians treating adult women who present with substance use concerns, the findings may support routine ADHD screening as part of the diagnostic evaluation. Identifying and treating underlying ADHD in women with substance use disorders could improve treatment outcomes by addressing a root cause of self-medication that conventional addiction treatment does not target.

Informing Treatment Guidelines

Current ADHD treatment guidelines do not differentiate recommendations by sex, despite growing evidence that ADHD manifests differently in females and may require different clinical approaches. If the MarketScan data reveals sex-specific patterns in treatment response and substance use risk, this evidence could support the development of guidelines that address the unique needs of females with ADHD -- including longer treatment durations, earlier intervention, and integrated substance use monitoring.

Addressing Health Equity

The underdiagnosis of ADHD in females represents a significant health equity issue. When a condition is systematically underrecognized in half the population, those individuals bear the burden of untreated illness -- with cascading effects on education, employment, relationships, and mental health. This research contributes to a broader effort to correct the male-centric bias in psychiatric diagnosis and treatment research.

Connection to Sultan Lab ADHD Research Program

The ADHD in Females study is one of several interconnected ADHD research projects within the Sultan Lab:

IQVIA National Prescribing Analysis: Examines national trends in stimulant prescribing, including the rapid increase in stimulant fills among females -- providing the prescribing-level complement to the MarketScan diagnostic analysis
JAMA Network Open 2019 Study: Dr. Sultan's landmark study of antipsychotic prescribing in ADHD youth used MarketScan data from the same database to examine treatment patterns following new ADHD diagnoses, establishing the methodological framework for the current study
JAMA Psychiatry 2025 Editorial: Analysis of protective effects of ADHD medication, including the finding that as more females enter the treated population, the relative benefit of medication on externalizing outcomes shifts -- suggesting that females with ADHD may benefit from medication through different pathways than males
ADHD in Women Clinical Resources: Evidence-based clinical information for women seeking ADHD evaluation and treatment

Research Team and Collaborators

Investigator	Role	Institution
Ryan S. Sultan, MD	Principal Investigator	Columbia University Irving Medical Center
Mark Olfson, MD, MPH	Senior Collaborator	Columbia University
Frances Levin, MD	K12 Mentor, Co-Investigator	Columbia University
Xuhai "Orson" Xu, PhD	NLP Technical Lead	Columbia University
Stephen Crystal, PhD	Collaborator (MarketScan Methods)	Rutgers University

Frequently Asked Questions

Why is ADHD underdiagnosed in females?

ADHD has historically been studied primarily in males, and diagnostic criteria were developed based on research in predominantly male samples. Females with ADHD more frequently present with inattentive symptoms rather than hyperactivity and impulsivity, making their symptoms less visible to parents, teachers, and clinicians. Girls with ADHD are more likely to develop compensatory strategies that mask their symptoms, often leading to diagnosis only after years of struggling. Additionally, ADHD symptoms in females may be attributed to anxiety, depression, or other conditions, leading to misdiagnosis rather than recognition of underlying ADHD.

What is the connection between ADHD and substance use in women?

Research has established that ADHD is a risk factor for substance use disorders, but most of this evidence comes from studies conducted primarily in males. The Sultan Lab's MarketScan study investigates whether females with ADHD face different substance use risks than males, including whether later diagnosis and treatment in females may create a longer window of vulnerability during which self-medication with substances is more likely. The study also examines whether consistent stimulant treatment is associated with reduced substance use risk in females with ADHD.

What is the MarketScan database used in this study?

The MarketScan Commercial Claims and Encounters database contains medical and pharmacy claims for over 200 million commercially insured individuals across the United States. It provides longitudinal data that allows researchers to follow individuals over time, tracking when they receive diagnoses, what medications they are prescribed, and what healthcare services they use. For this study, MarketScan data enables the research team to identify females with ADHD diagnoses, track their treatment patterns, and examine subsequent substance use-related diagnoses and healthcare utilization.

How does this study differ from other ADHD-in-women research?

Most existing research on ADHD in females relies on clinical samples or cross-sectional surveys. The Sultan Lab's MarketScan study uses longitudinal commercial insurance claims data covering millions of individuals, allowing the team to examine real-world treatment patterns and outcomes over time rather than relying on single-point assessments. The study also specifically examines the relationship between ADHD treatment and substance use outcomes in females -- a question that has been largely unaddressed because prior studies either combined males and females or excluded females due to small sample sizes.

Sultan Lab for Mental Health Informatics - Full lab overview
ADHD in Women - Clinical information and resources
ADHD and Substance Use - Understanding the connection
Blog: ADHD Diagnosis in Women - Clinical perspectives
IQVIA Prescribing Analysis - National stimulant prescribing trends
Complete Publication List - Peer-reviewed research
Research Grants & Funding - Grant details